IL15 and neoplasm: Ultimately, by targeting the tumor-associated antigen Wilms’ tumor-1 (WT1), the tumor-antigen specificity was assessed by demonstrating a superior antigen-specific T cell stimulating capacity of PD-L-silenced IL-15 DCs.